TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of 5 mg Sublingual Zolpidem vs 10mg Oral Zolpidem in the Induction and Maintenance of Sleep in Patients With Primary Insomnia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women aged between 20 and 64 years;~* Diagnosis of primary insomnia according to criteria defined by DSM-IV;~* Difficulty in maintaining sleep and waking up until 3 am;~* Not having used any psychoactive drug in the last 30 days prior to their inclusion in the study;~* Signature of IC.~Exclusion Criteria:~* Previous history of serious medical illness, neurological or psychiatric disorder;~* Allergy or hypersensitivity to zolpidem;~* Obstructive Sleep Apnea syndrome;~* Polysomnography with apnea and hypopnea index \>10/hour or PLM \>15/h;~* Other secondary sleep disorders;~* History of substance abuse or dependence;~* History of daily consumption of alcoholic beverages;~* Pregnancy, lactation or refusal to use safe contraceptive methods during the study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- 5mg sublingual Zolpidem hemitartrate (Type: EXPERIMENTAL): 1 QD
- 10 mg oral Zolpidem hemitartrate (Type: ACTIVE_COMPARATOR): 1 QD.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing the Intravenous Treatment of Skin Infections in Children, Home Versus Hospital

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children aged 6 months to 18 years~* Children presenting to RCH ED with moderate/severe cellulitis~* Moderate/severe: defined in this study, as those assessed by ED clinician to need IV antibiotics~* Reasons for starting IV antibiotics include:~  1. Failed oral therapy (not improving despite 24h of oral therapy)~ 2. Rapidly spreading redness (from patient/parent history)~ 3. Significant swelling/redness/pain~ 4. Systemic symptoms/signs (eg. fever, lethargy)~ 5. Difficult to treat areas (eg. face, ear, toe)~Exclusion Criteria:~Children will be excluded:~1. With orbital cellulitis or unable to exclude orbital cellulitis,~2. With penetrating injury/bites,~3. With suspected fasciitis or myositis,~4. With toxicity: tachycardia when afebrile or hypotension (both as per the limits set out by RCH Resuscitation Card), poor central perfusion (capillary refill \>2 seconds)~5. With immunosuppression,~6. With varicella,~7. With suspected/confirmed foreign body,~8. With abscess not drained,~9. With dental abscess,~10. With concurrent sinusitis or otitis media or lymphadenitis necessitating different antibiotic treatment to flucloxacillin monotherapy or ceftriaxone monotherapy,~11. With liver co-morbidities~12. With other medical diagnoses warranting admission to hospital for observation or treatment relating to the known medical condition~13. With difficult intravenous access,~14. Age \<6 months old,~15. Who could be managed on oral antibiotics (ie assessed as mild cellulitis)

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Home (Type: EXPERIMENTAL): Patients will be treated at home through the Hospital-In-The-Home program with intravenous once daily ceftriaxone (50mg/kg once daily), administered by a nurse/doctor visiting once daily.
- Ward (Type: ACTIVE_COMPARATOR): Patients will be admitted to hospital ward and treated with six hourly flucloxacillin (50mg/kg), administered by a ward nurse as per routine practice.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Immunologically confirmed diagnosis of B-cell CLL~* Rai stage I-IV disease with evidence of progression~* No previous chemotherapy, radiotherapy, or immunotherapy for B-cell CLL~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2~Exclusion Criteria:~* Active secondary malignancy or transformation to aggressive lymphoma~* Medical condition requiring chronic use of oral corticosteroids at a dose of 1 mg/kg or 60 mg/m\^2 over 2 weeks~* Prior treatment with interferon, rituximab or another monoclonal antibody, immunosuppressive treatment or radiotherapy before inclusion to the study~* History of other malignancies within 2 years before study entry, except for dequately treated carcinoma in situ of the cervix; basal or squamous cell skin cancer; low grade, early stage localized prostate cancer treated surgically with curative intent; good prognosis ductal carcinoma in situ (DCIS) of the breast treated with lumpectomy alone with curative intent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Induction: Rituximab, Cladribine, Cyclophosphamide (Type: EXPERIMENTAL): Participants will receive rituximab at a dose of 375 milligrams per meter squared (mg/m\^2) as intravenous (IV) infusion on Day 1, cladribine at a dose of 0.12 milligrams per kilogram per day (mg/kg/day) as IV infusion on Days 2-4, and cyclophosphamide at a dose of 250 mg/m\^2/day as IV infusion over 15-30 minutes on Days 2-4 in Cycle 1. Then, rituximab at a dose of 500 mg/m\^2 as IV infusion on Day 1, cladribine at a dose of 0.12 mg/kg/day as IV infusion on Days 2-4, and cyclophosphamide at a dose of 250 mg/m\^2/day as IV infusion over 15-30 minutes on Days 2-4 will be administered in Cycles 2-6. Each cycle will be of 28 days in duration.
- Maintenance Arm: Rituximab (Type: EXPERIMENTAL): Participants with PR or CR after induction phase who will be randomized to maintenance arm will receive rituximab treatment for 8 cycles. Twelve weeks after the last induction cycle, participants will receive rituximab at a dose of 375 mg/m\^2 as IV infusion on Day 1 of each 12-week cycle until disease progression (up to approximately 96 weeks).
- Observation Arm: No Intervention (Type: NO_INTERVENTION): Participants with PR or CR after induction phase who will be randomized to observation arm will not receive any intervention. Participants will be assessed every 4-weeks for the first 12 weeks and every 12-weeks afterwards up to 96 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of GBS Colonization Via Immunity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participated in and completed the group B Streptococcus (GBS) Screening Protocol~* Non-pregnant women~* Aged 18-40 years at time of the screening protocol~* Currently sexually active at time of enrollment (sex with a male at least once in the last 4 months)~* Current use of effective birth control methods and stated intention to use the method for at least the next 30 days~* Provision of written informed consent~* Intention to stay in the geographical area for the next 18 months~* Access to telephone~Exclusion Criteria:~* Group B Streptococcus (GBS) positive by culture (vaginal and/or rectal), or culture positive for streptococcal strains that cross-react with GBS typing sera (vaginal and/or rectal).~* Pregnancy (all women will receive a urine pregnancy prior to vaccination).~* Any condition which in the opinion of the investigator would pose a health risk to the subject or interfere with the evaluation of the vaccine.~* Serious underlying disease, which is known at the time of vaccination (including: immunodeficiency, active or chronic hepatitis, immunosuppressive conditions which require systemic steroid therapy, or treatment for a malignancy during the past year).~* Receipt of any vaccine, blood product, or experimental medicine within the past 30 days with the exception of a licensed inactivated influenza vaccine.~* Plans to receive any vaccine, blood product, or experimental medicine in the next 30 days with the exception of a licensed inactivated influenza vaccine.~* Use of any antimicrobial agent(s) (vaginal or systemic) for treatment of any condition within 7 days prior to study enrollment (including: Monistat, Gyne-Lotrimin, et cetera )~* History of hypersensitivity to tetanus toxoid vaccine.~* Tetanus toxoid immunization within the previous 12 months.~* Previous participation in a study in which participants received tetanus toxoid vaccine or vaccine against Group B Streptococcus.~* Spontaneous or surgical menopause.~* Nursing mother.~* Hypersensitivity to thimerosal.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- GBS III-TT (Type: EXPERIMENTAL): A single dose of GBS III-TT vaccine administered intramuscularly (IM) containing 50 mcg of GBS III capsular polysaccharide and 32 mcg of tetanus toxoid.
- Td (Type: ACTIVE_COMPARATOR): The control group will receive a single dose of Tetanus and Diphtheria Toxoids (Td) vaccine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of schizophrenia~* Ability to remain hospitalized for at least first 4 weeks of study~* Needs hospitalization due to worsening of schizophrenia~Exclusion Criteria:~* Type 1 or 2 diabetes~* Previous use of clozapine~* Serious medical illness other than schizophrenia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria (MRA011JP patients)~* Of the patients who received the three infusions of MRA at the same dose in the main evaluation period in the previous study and are currently in the continued treatment period~* the patients in whom it is confirmed that the drug is effective and there are no problems with safety (MRA316JP patients)~* Patients who proceed to the blind period and in whom the last observations are done after study completion or withdrawal~* Patients who receive the three infusions in the open-label period and do not meet the criteria for transition to the blind period~Exclusion criteria~* Patients who were not enrolled by 3 months after completion of the previous study~* Patients who have been treated with infliximab or etanercept from completion of the previous study until the start of treatment in this study

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 19 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Short-term Effects of Perindopril-amlodipine Versus Perindopril-indapamide in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult diabetes patients aged between 25-65 years,~* with grade I or grade II (WHO classification) hypertension on the clinical measure, confirmed by ABPM~* naïve to any anti-hypertensive treatment~* written informed consent.~Exclusion Criteria:~* Patients with grade III hypertension (WHO classification) were classified as hypertensive emergency,~* estimated creatinine clearance ˂30ml/min/1.73m2 (using Modified Diet in Renal Diseases formula)~* alanine transaminase (ALT)≥ 3 normal~* any contraindication to study drugs (hypersensitivity)~* pregnant or breastfeeding women

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Perindopril and Amlodipine (Type: EXPERIMENTAL): Fixed dose combination of Perindopril 5mg and Amlodipine 5mg tablets once daily for 6 weeks
- Perindopril-Indapamide (Type: ACTIVE_COMPARATOR): Fixed-dose combination of Perindopril 5mg and Indapamide 1.25mg tablets once daily for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multihance Versus Magnevist in Breast MRI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Provides written informed consent~* Female~* Age 18 years or older~* Suspicious or known breast lesion based on results from mammography or ultrasound~* Planned to undergo histological diagnosis of breast lesion by having a non surgical biopsy or breast surgery within 30 days after the MRI exam~Exclusion Criteria:~* Body weight \> 100 kg~* Pregnant or lactating~* Server or end-stage organ failure~* Moderate to severe renal impairment~* Undergoing radiotherapy or completed radiotherapy in the last 18 months~* Chemotherapy within 6 months of the 1st MRI exam

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Crossover Study in the Treatment of Patients With COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of COPD~* Smoker or exsmoker with at least 10 years smoking at least one pack of cigarettes per day~* Meet lung function requirements~Exclusion Criteria:~* Diagnosis of Asthma~* Significant disease other than COPD~* Female pregnant or lactating or planning to become pregnant

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: AMG 162 (Denosumab) Phase 3 Study (DESIRABLE Study) in Participants With Rheumatoid Arthritis on Disease-modifying Antirheumatic Drugs (DMARDs) Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with rheumatoid arthritis according to the American College of Rheumatology (ACR) criteria for rheumatoid arthritis classification (1987 revision) or the 2010 ACR-EULAR (The European League Against Rheumatism) classification criteria for rheumatoid arthritis~Exclusion Criteria:~* Functional class IV according by the ACR revised classification (1991)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Denosumab 6 months (Type: EXPERIMENTAL): denosumab administered subcutaneously every 6 months
- Denosumab 3 months (Type: EXPERIMENTAL): denosumab administered subcutaneously every 3 months
- placebo (Type: PLACEBO_COMPARATOR): placebo administered subcutaneously to match denosumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Unresectable locally advanced or metastatic HCC, which must be confirmed by histologically or cytologically. Fibrolamellar, sarcomatoid, or mixed cholangiocarcinoma histology confirmed by histologically or cytologically is excluded.~2. Barcelona Clinic Liver Cancer (BCLC) Stage C disease or BCLC Stage B disease that is not amenable to or has progressed after loco-regional therapy and is not amenable to a curative treatment approach~3. Did not receive any systemic treatment before and is unwilling to accept standard of care treatment or not suitable for standard of care treatment as judged by investigators~4. European Cancer Oncology Group (ECOG) Performance Status ≤ 1~5. Child-Pugh A classification for liver function assessed within 7 days of first dose of study drugs~Key Exclusion Criteria:~1. Active autoimmune diseases or history of autoimmune diseases that may relapse~2. Any active malignancy ≤ 2 years before the first dose of study drugs except for specific cancer under investigation in this study and any locally recurring cancer that has been treated curatively (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast)~3. Uncontrolled diabetes or \> Grade 1 laboratory test abnormalities in potassium, sodium, or corrected calcium despite standard medical management, or ≥ Grade 3 hypoalbuminemia ≤ 14 days before the first dose of study drugs~4. Any known brain or leptomeningeal metastases~5. Concurrent participation in another therapeutic clinical study~NOT: Other protocol defined Inclusion/Exclusion criteria may apply NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Part 1: Safety Run-in (Type: EXPERIMENTAL): Lenvatinib at a dose of 8 mg or 12 mg based on body weight + tislelizumab for one 21-day cycle
- Part 2: Lenvatinib (Type: EXPERIMENTAL): Lenvatinib at the recommended phase 2 dose (RP2D) determined from Part 1 + tislelizumab in 21-day cycles for up to 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Maintenance Treatment for Abstinent Smokers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who smoke at least 10 cigarettes daily and have attempted to quit smoking at least once~Exclusion Criteria:~* Seizure History~* Unstable Blood Pressure~* Current major depression~* Current alcohol/drug abuse or dependency~* Lifetime psychotic illness~* Current use of psychotropic drugs~* Unstable medical condition

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Bupropion (Type: ACTIVE_COMPARATOR): Bupropion (brand name Zyban Sustained Release). Participants used bupropion SR 150 mg twice daily during the 16-week maintenance treatment.
- Nicotine gum (Type: ACTIVE_COMPARATOR): Nicotine gum (brand name Nicorette) During the maintenance 16-week maintenance treatment phase, participants assigned to this arm received 2 mg. nicotine gum.
- Bupropion+Nicotine Gum (Type: ACTIVE_COMPARATOR): Combined active treatments: Bupropion (Zyban SR) and nicotine gum (Nicorette). Participants were instructed to use the 150 mg bupropion pill twice daily and the 2 mg. gum as needed during the 16-week maintenance treatment phase.
- Double placebo (Type: PLACEBO_COMPARATOR): Placebo gum + placebo pill. Identical placebo pill was used twice daily and identical placebo gum was used as needed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: IMPROVE HF: Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Primary or secondary diagnosis of heart failure or prior myocardial infarction (heart attack)~* Moderate-to-severe left ventricular dysfunction (LVD) as demonstrated by an ejection fraction \< or = 35% and/or a qualitative assessment of LVD of moderate-to-severe or severe LVD~* Patient has been seen at the clinic at least twice in the past 2 years~* Patient received care from the physician participating in the study~Exclusion Criteria:~* Patient has died~* Patient is not expected to survive for 12 months due to medical conditions other than heart failure~* Patient has undergone heart transplant surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A (longitudinal) (Type: None): Longitudinal Cohort: Approximately 15,000 patients followed at baseline, 12 months and 24 months
- Cohort B (6 Month) (Type: None): 6 Month Cohort: Approximately 10,000 patients reviewed at single time point
- Cohort C (18 Month) (Type: None): 18 Month Cohort: Approximately 10,000 patients reviewed at single time point

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete